首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1550704

全球Bortezomib市場：按產品類型、按應用、按最終用戶、按地區

Bortezomib Market, By Product Type, By Application, By End User, By Geography

出版日期: 2024年08月22日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球Bortezomib市場規模為2,454萬美元，預計2031年將達3,315萬美元，2024年至2031年複合年成長率為4.4%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	2454萬美元
實際資料	2019-2023	預測期	2024-2031
預測 2024-2031 年複合年成長率：	4.40%	2031年價值預測	3315萬美元

圖：2024 年按地區分類的Bortezomib市場佔有率(%)

Bortezomib（通常稱為 Velcade）是一種蛋白酶體抑制劑，可作為標靶癌症治療藥物。Bortezomib已被證明是治療多發性骨髓瘤和其他癌症的有效選擇。全球癌症盛行率不斷上升，加上老年人口越來越容易罹患骨髓瘤，可能會推動Bortezomib的需求。由於Bortezomib被指定為孤兒藥，製造商正在積極投資該市場。然而，藥物專利到期可能會阻礙市場成長。Bortezomib令人鼓舞的治療功效和不斷擴大的應用可能會在不久的將來為全球Bortezomib市場的成長提供利潤豐厚的機會。

市場動態：

全球Bortezomib市場的成長是由全球癌症負擔日益增加所推動的。市場成長的原因是多發性骨髓瘤盛行率不斷上升、對該疾病的核准增加以及更容易患骨髓瘤的老年人口不斷增加。據美國國家癌症美國稱，2020 年美國報告了超過 15 萬例多發性骨髓瘤病例。此外，與Bortezomib相關的高治療成本和研發成本可能會阻礙市場成長。創新藥的專利將於2015年至2020年間到期，這將鼓勵學名藥的生產，並可能對原廠藥Velcade的銷售產生負面影響。然而，正在進行的評估Bortezomib在其他疾病中的潛力的試驗可能會帶來新的機會。

本研究的主要特點

本報告對全球Bortezomib市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球Bortezomib市場的主要企業進行了分析。

本研究涵蓋的主要企業包括強生公司、工業、Fresenius SE &Co.KGaA、Dr. Reddy's Laboratories Ltd 和 Scion Pharma LLC。

從這份報告中獲得的見解將幫助負責人和公司經營團隊就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。

全球Bortezomib市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球Bortezomib市場的各種策略矩陣，將有助於相關人員做出決策。

Hikma Pharmaceuticals
Pfizer
Meitheal Pharmaceuticals
Novartis International AG
Bristol Myers Squibb
NATCO Pharma
Teva Pharmaceuticals
Reddy's Laboratories
Gland Pharma
Shilpa Medicare
Qilu Pharmaceutical
Scion Pharmaceuticals
Farmhispania Group
Coresyn
Chem-Stone（Guangzhou）
Hubei Honch Pharmaceutical
Vinkem Labs
Icrom
TAPI Teva
Chengdu Aslee Biopharmaceuticals

第9章分析師建議

Wheel of Fortune
分析師觀點
Coherent Opportunity Map（COM）

第10章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI7281

Global bortezomib market is estimated to be valued at USD 24.54 Mn in 2024 and is expected to reach USD 33.15 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 24.54 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	4.40%	2031 Value Projection:	US$ 33.15 Mn

Figure. Bortezomib Market Share (%), By Region 2024

Bortezomib, commonly known as Velcade, is a proteasome inhibitor that acts as a targeted cancer therapy. It has proven to be an effective treatment option for multiple myeloma and other cancers. Increasing prevalence of cancer worldwide along with growing geriatric population susceptible to myeloma can boost demand for Bortezomib. Drug being designated with orphan drug status has encouraged manufacturers to invest in this market. However, patent expiry of the drug can hamper the market growth. Promising therapeutic efficacy and expanding applications of Bortezomib can offer lucrative opportunities for the global bortezomib market growth in the near future.

Market Dynamics:

Global bortezomib market growth is driven by rising cancer burden globally. The market growth can be attributed to increasing incidence rates of multiple myeloma, approval for additional indications, and expanding geriatric population base who are more prone to developing myeloma. As per the National Cancer Institute, more than 150,000 cases of multiple myeloma were reported in the US in 2020. High treatment and R&D costs associated with Bortezomib can hamper the market growth. Patent expiry of innovative drug between 2015 to 2020 has encouraged production of generic versions, and this can negatively impact the sales of branded Velcade. However, ongoing trials evaluating the potential of Bortezomib in other disease indications can present new opportunities.

Key features of the study:

This report provides in-depth analysis of the global bortezomib market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global bortezomib market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Johnson & Johnson, Takeda Pharmaceutical Company Ltd, Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Ltd, and Scion Pharma LLC

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global bortezomib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bortezomib market

Detailed Segmentation-

By Product Type Insights (Revenue, USD Mn, 2019 - 2031)
- Injection
- Powder for Injection
By Application Insights (Revenue, USD Mn, 2019 - 2031)
- Multiple Myeloma
- Mantle Cell Lymphoma
- Other Hematological Malignancies
By End User Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals
- Oncology Clinics
- Ambulatory Surgical Centers
- Others (Research Institutes, Cancer Centers)
By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Hikma Pharmaceuticals
- Pfizer
- Meitheal Pharmaceuticals
- Novartis International AG
- Bristol Myers Squibb
- NATCO Pharma
- Teva Pharmaceuticals
- Reddy's Laboratories
- Gland Pharma
- Shilpa Medicare
- Qilu Pharmaceutical
- Scion Pharmaceuticals
- Farmhispania Group
- Coresyn
- Chem-Stone (Guangzhou)
- Hubei Honch Pharmaceutical
- Vinkem Labs
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Bortezomib Market, By Product Type
- Global Bortezomib Market, By Application
- Global Bortezomib Market, By End User
- Global Bortezomib Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Bortezomib Market, By Product Type, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Powder for Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Bortezomib Market, By Application, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Mantle Cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Other Hematological Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Bortezomib Market, By End User, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Oncology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others (Research Institutes, Cancer Centers)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Bortezomib Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 220 - 2031, (USD Mn)
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Meitheal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
NATCO Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gland Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shilpa Medicare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Qilu Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Scion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Farmhispania Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Coresyn
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chem-Stone (Guangzhou)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hubei Honch Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Vinkem Labs
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Icrom
TAPI Teva
Chengdu Aslee Biopharmaceuticals